Capsule Summary Slidesets

Share

Program Content

Activities

  • LIBERTY AD PEDS Results
    LIBERTY AD PEDS Study Results: Efficacy and Safety of Dupilumab in Children Aged ≥ 6 to < 12 Yrs With Severe Atopic Dermatitis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 20, 2020

    Expires: July 19, 2021

  • JADE MONO-2 Results
    JADE MONO-2 Study Results: Efficacy and Safety of Abrocitinib in Patients With Moderate to Severe Atopic Dermatitis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 20, 2020

    Expires: July 19, 2021

  • Upadacitinib Treatment Withdrawal and Retreatment
    Efficacy and Safety of Treatment Withdrawal and Retreatment With Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 27, 2020

    Expires: July 26, 2021

  • BREEZE-AD1/2 Pooled Data Results
    Pooled Data From BREEZE-AD1 and BREEZE-AD2 Examining the Efficacy and Safety of Baricitinib in Patients With Atopic Dermatitis and Atopic Comorbidities
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 27, 2020

    Expires: July 26, 2021

  • Dupilumab for Erythrodermic AD
    Dupilumab for Erythrodermic AD: Results From a Pooled Subgroup Analysis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 27, 2020

    Expires: July 26, 2021

  • BREEZE-AD5 Results
    BREEZE-AD5 Study Results: Efficacy and Safety of Baricitinib in Patients With Moderate to Severe Atopic Dermatitis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 11, 2020

    Expires: August 10, 2021

Provided by

ProCE Banner

Supporters

AbbVie Inc.

Pfizer, Inc.